Piper Sandler Initiates Coverage on Definium Therapeutics (NASDAQ:DFTX)

Analysts at Piper Sandler began coverage on shares of Definium Therapeutics (NASDAQ:DFTX) in a research note issued to investors on Friday, Marketbeat reports. The firm set an “overweight” rating and a $49.00 price target on the stock. Piper Sandler’s price target would suggest a potential upside of 127.59% from the company’s current price.

Other equities analysts have also recently issued reports about the stock. JonesTrading initiated coverage on shares of Definium Therapeutics in a research note on Tuesday, December 23rd. They issued a “buy” rating and a $61.00 price objective on the stock. Royal Bank Of Canada lifted their target price on shares of Definium Therapeutics from $20.00 to $36.00 and gave the stock an “outperform” rating in a report on Friday, January 23rd. Wolfe Research initiated coverage on Definium Therapeutics in a research report on Monday, February 23rd. They issued an “outperform” rating and a $25.00 price target on the stock. HC Wainwright raised their price target on Definium Therapeutics from $55.00 to $70.00 and gave the stock a “buy” rating in a research report on Monday, March 2nd. Finally, Needham & Company LLC restated a “buy” rating on shares of Definium Therapeutics in a research report on Monday, January 5th. Two analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $36.91.

Definium Therapeutics Stock Up 0.5%

Shares of NASDAQ:DFTX opened at $21.53 on Friday. Definium Therapeutics has a one year low of $5.05 and a one year high of $22.12. The company has a 50 day moving average of $18.14 and a 200-day moving average of $14.78. The company has a debt-to-equity ratio of 0.12, a current ratio of 6.29 and a quick ratio of 6.29. The stock has a market cap of $2.15 billion, a price-to-earnings ratio of -10.11 and a beta of 2.44.

Institutional Trading of Definium Therapeutics

Hedge funds have recently modified their holdings of the company. Russell Investments Group Ltd. increased its position in shares of Definium Therapeutics by 110.4% in the 2nd quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock valued at $25,000 after buying an additional 2,003 shares in the last quarter. BIT Capital GmbH bought a new stake in shares of Definium Therapeutics in the 3rd quarter valued at $26,000. Fifth Third Bancorp increased its position in shares of Definium Therapeutics by 5,593.2% in the 3rd quarter. Fifth Third Bancorp now owns 3,359 shares of the company’s stock valued at $40,000 after buying an additional 3,300 shares in the last quarter. Sound Income Strategies LLC bought a new stake in shares of Definium Therapeutics in the 3rd quarter valued at $46,000. Finally, BNP Paribas Financial Markets increased its position in shares of Definium Therapeutics by 56.0% in the 2nd quarter. BNP Paribas Financial Markets now owns 8,417 shares of the company’s stock valued at $55,000 after buying an additional 3,020 shares in the last quarter. 27.91% of the stock is currently owned by institutional investors and hedge funds.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.